Who is sponsoring NCT00133354?

NCT00133354 is sponsored by Nemours Children's Clinic.

What condition does NCT00133354 study?

NCT00133354 studies Hypopituitarism.

What drugs are being tested in NCT00133354?

Interventions: Arimidex (Anastrozole), Placebo, Growth Hormone.

What is the status of NCT00133354?

NCT00133354 is currently COMPLETED.

Last reviewed 2011-10-11 · How we verify

Double-blind Trial Investigating the Safety and Efficacy of the Inhibitor Anastrozole (ARIMIDEX) in Delaying Epiphyseal Fusion and Increasing Height Potential of Adolescent Males With Growth Hormone (GH) Deficiency

NCT00133354 Phase 2/Phase 3 COMPLETED

The purpose of this study is to see if Arimidex, an aromatase inhibitor, can delay epiphyseal fusion and increase predicted adult height in boys who are growth hormone deficient, in puberty, and who are taking growth hormone. This is a double blind, placebo controlled 3 year trial.

Details

Lead sponsor	Nemours Children's Clinic
Phase	Phase 2/Phase 3
Status	COMPLETED
Enrolment	53
Start date	2001-11
Completion	2010-08

Conditions

Hypopituitarism

Interventions

Arimidex (Anastrozole)
Placebo
Growth Hormone

Primary outcomes

The primary measure of efficacy is change in predicted adult height based on rate of bone age advancement. — 12months, 24months, 36months

Countries

United States